aflibercept

consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders

Also Known As:

Networked: 340 relevant articles (58 outcomes, 113 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Vitti, Robert: 17 articles (10/2015 - 06/2011)
2.	Berliner, Alyson J: 17 articles (10/2015 - 11/2009)
3.	Heier, Jeffrey S: 13 articles (10/2015 - 06/2011)
4.	Brown, David M: 13 articles (10/2015 - 06/2011)
5.	Zeitz, Oliver: 12 articles (10/2015 - 05/2012)
6.	Kaiser, Peter K: 12 articles (10/2015 - 03/2012)
7.	Schmidt-Erfurth, Ursula: 11 articles (10/2015 - 09/2011)
8.	Do, Diana V: 10 articles (01/2016 - 11/2009)
9.	Sandbrink, Rupert: 10 articles (04/2015 - 09/2011)
10.	Nguyen, Quan Dong: 9 articles (01/2016 - 11/2009)

Related Diseases

1.	Macular Degeneration (Age-Related Maculopathy) 03/01/2015 - "Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration." 12/01/2015 - "To prospectively assess the safety and efficacy of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration (nAMD). " 10/01/2015 - "Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). " 05/01/2015 - "To investigate the efficacy of periodic injection of aflibercept in each subtype of age-related macular degeneration (AMD) and to explore the predictive factors for visual outcome in clinical settings. " 01/01/2015 - "In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline. "
2.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2012 - "Aflibercept is a novel angiogenesis-targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. " 05/01/2015 - "[Sequential inhibition of angiogenesis in metastatic colorectal cancer: activity and efficacy of aflibercept]." 11/01/2014 - "Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer." 11/01/2012 - "We assessed the safety and efficacy of aflibercept in patients with metastatic colorectal cancer (MCRC) who had received at least one prior palliative regimen. " 09/29/2015 - "Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting."
3.	Macular Edema 11/01/2014 - "Patients with macular edema following CRVO benefited from early treatment with intravitreal aflibercept." 10/01/2015 - "Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies." 03/01/2015 - "Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study." 11/01/2014 - "Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study." 07/01/2014 - "Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study."
4.	Choroidal Neovascularization 06/01/2015 - "Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study." 08/01/2012 - "Preclinical ophthalmologic studies demonstrated that aflibercept suppresses choroidal neovascularization in several animal models. " 06/01/2015 - "To evaluate intravitreal aflibercept 2 mg in patients with myopic choroidal neovascularization (CNV). " 01/01/2013 - "The availability of agents with alternative molecular structures, such as aflibercept, may permit additional insights into the complex relationship between choroidal neovascularization, vitritis, and innate and other immunologic processes." 12/01/2012 - "In this double-masked, phase 1 study, 28 patients with lesions ≤12 disc areas, ≥50% active choroidal neovascularization (CNV), and best corrected visual acuity (BCVA) ≤20/40 were randomized 1:1 to a single intravitreal injection of aflibercept 0.15 or 4 mg. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/01/2012 - "Results from the phase III study, VITAL, of aflibercept in the second-line setting in patients with advanced non-small cell lung cancer [NCT00532155] demonstrated efficacy in progression-free survival and overall objective response rate, but overall survival was not significantly improved. " 02/04/2014 - "This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). " 02/04/2014 - "A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer." 10/10/2012 - "Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial." 01/01/2013 - "The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer. "

Related Drugs and Biologics

1.	ranibizumab (Lucentis)
2.	bevacizumab
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	oxaliplatin (Eloxatin)
5.	aflibercept
6.	irinotecan (Camptosar)
7.	velour
8.	docetaxel (Taxotere)
9.	salicylhydroxamic acid (SHAM)
10.	Retinaldehyde (Retinal)

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Injections
3.	Drug Therapy (Chemotherapy)
4.	Lasers (Laser)
5.	Light Coagulation